Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 2/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
| ▸ | FNTA | P49354 | 1/20 | 0.30 |
| ▸ | FNTB | P49356 | 1/20 | 0.30 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16226749 | 0.90 | THRB (0.37) | TBXAS1THRBFNTAFNTBPGGT1B | |
| SCHEMBL8465648 | 0.79 | TBXAS1 (0.36) | TBXAS1 | |
| SCHEMBL1217777 | 0.79 | TBXAS1 (0.38) | TBXAS1 | |
| SCHEMBL14120426 | 0.78 | THRB (0.35) | TBXAS1THRBFNTAFNTBPGGT1B | |
| SCHEMBL5006417 | 0.77 | TBXAS1 (0.41) | TBXAS1THRBFNTAFNTBPGGT1B | |
| SCHEMBL2132778 | 0.77 | THRB (0.34) | TBXAS1THRBFNTAFNTBPGGT1B | |
| SCHEMBL14120856 | 0.76 | TBXAS1 (0.36) | TBXAS1THRBFNTAFNTBPGGT1B | |
| SCHEMBL2133790 | 0.75 | THRB (0.35) | TBXAS1THRBFNTAFNTBPGGT1B | |
| SCHEMBL3899872 | 0.75 | TSHR (0.33) | TBXAS1THRBFNTAFNTBPGGT1B | |
| SCHEMBL14121245 | 0.74 | TBXAS1 (0.39) | TBXAS1THRBFNTAFNTBPGGT1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140336196-A1 | PHOSPHORIC ACID SALTS OF SITAGLIPTIN | MERCK SHARP & DOHME CORP. (US) | 2014-11-13 | — | — | US | claimed |
| US-20140336196-A1 | PHOSPHORIC ACID SALTS OF SITAGLIPTIN | MERCK SHARP & DOHME CORP. (US) | 2014-11-13 | — | — | US | disclosed |
| US-20140335154-A1 | METHODS AND FORMULATIONS TO ACHIEVE TUMOR TARGETED DOUBLE STRANDED RNA MEDIATED CELL DEATH | MULTICELL IMMUNOTHERAPEUTICS, INC. (US) | 2014-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140336196-A1 | PHOSPHORIC ACID SALTS OF SITAGLIPTIN | DPP4, DPP7, DPP3 | TBXAS1 1370/4885THRB 1459/4885FNTA 3349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.